“The TALAPRO-2 results showed that TALZENNA plus XTANDI is the first and only PARP inhibitor in combination with an ARPI to significantly improve survival in patients with metastatic ...

Pfizer’s Talzenna has been holding onto a breast cancer nod while three other marketed peers battle it out in ovarian cancer. But with a pivotal trial win, the PARP inhibitor outlier is poised to join ...

TALAPRO-2 trial shows Talzenna plus Xtandi improves median OS by 8.8 months in mCRPC patients, reducing death risk by 20.4%. HRR-deficient patients benefit more, with a 38% reduction in death risk and ...

TALZENNA + XTANDI is the first PARP inhibitor plus ARPI combination to demonstrate statistically significant and clinically meaningful improvement in overall survival (OS) in patients with metastatic ...

Pfizer may be the last major oncology player to put a wager on a PARP inhibitor in prostate cancer, but the New York pharma appears to have a winning regimen, partly thanks to its Astellas-partnered ...

Talzenna (talazoparib) is a brand-name drug that’s prescribed for certain types of breast and prostate cancers in adults. It comes as an oral capsule that’s typically taken once per day. The dosage ...

A U.S. FDA panel of independent experts beat back an effort by Pfizer (NYSE:PFE) to expand the patient population for its prostate cancer treatment Talzenna (talazoparib). Members of the Oncologic ...

Adding Talzenna (talazoparib) to Xtandi (enzalutamide) improved the length of time men with metastatic castration-resistant prostate cancer lived before their disease worsened, compared to those who ...

Credit: Pfizer. Talzenna, a poly (ADP-ribose) polymerase (PARP) inhibitor, was evaluated in EMBRACA, an open-label trial that randomized patients with gBRCAm HER2-negative locally advanced or ...

First and only PARP inhibitor plus ARPI combination to demonstrate statistically significant overall survival (OS) benefit in patients with metastatic castration-resistant prostate cancer (mCRPC) ...

On Thursday, Pfizer Inc. (NYSE:PFE) revealed results from the Phase 3 TALAPRO-2 study of Talzenna (talazoparib) in combination with Xtandi (enzalutamide). The trial demonstrated a statistically ...